Dr. Reckamp on Current Heat Shock Protein Clinical Trials

Karen Reckamp, MD
Published: Monday, Aug 22, 2011

Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, describes the various clinical studies currently underway examining the use of heat shock proteins.

Clinical trials are currently looking specifically at ALK translocated, crizotinib resistance, and patient that have not yet received crizotinib. Further examination is being completed into heat shock proteins in combination with docetaxel and other targets and biomarkers that specify which patients will have the most benefit.
Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, describes the various clinical studies currently underway examining the use of heat shock proteins.

Clinical trials are currently looking specifically at ALK translocated, crizotinib resistance, and patient that have not yet received crizotinib. Further examination is being completed into heat shock proteins in combination with docetaxel and other targets and biomarkers that specify which patients will have the most benefit.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x